IMI/REL FDC
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Suspected or Documented Gram-negative Bacterial Infection
Conditions
Suspected or Documented Gram-negative Bacterial Infection
Trial Timeline
Nov 6, 2017 → Aug 11, 2020
NCT ID
NCT03230916About IMI/REL FDC
IMI/REL FDC is a phase 1 stage product being developed by Merck for Suspected or Documented Gram-negative Bacterial Infection. The current trial status is completed. This product is registered under clinical trial identifier NCT03230916. Target conditions include Suspected or Documented Gram-negative Bacterial Infection.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03230916 | Phase 1 | Completed |
Competing Products
6 competing products in Suspected or Documented Gram-negative Bacterial Infection
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| KHK4563 + KHK4563 + KHK4563 + Placebo | Kyowa Kirin | Phase 2 | 52 |
| Ceftazidime-avibactam | AbbVie | Phase 1 | 33 |
| IMI/REL + Active Control + Oral Switch | Merck | Phase 2/3 | 65 |
| Ceftolozane/Tazobactam 1000/500 mg + Ceftolozane/Tazobactam 30/15 mg/kg + Ceftolozane/Tazobactam 20/10 mg/kg + Ceftolozane/Tazobactam 18/9 mg/kg + Ceftolozane/Tazobactam 12/6 mg/kg | Merck | Phase 1 | 33 |
| Gadoxetic Acid Disodium (Primovist, BAY86-4873) | Bayer | Phase 3 | 74 |
| TD-1607 + Placebo | Theravance Biopharma | Phase 1 | 28 |